RLAY
Relay Therapeutics Inc
1 day chart
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to address drug-protein targets that have previously been intractable or inadequately addressed. The Company’s product candidates are RLY-4008, RLY-2608, and GDC-1971. RLY-4008 is an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), for patients with advanced or metastatic FGFR2-altered solid tumors. RLY-2608 is a pan-mutant (H1047X, E542X, and E545X) and isoform-selective phosphoinositide 3 kinase alpha (PI3Ka) inhibitor. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Buy US stocks in Australia starting with RLAY. Open an account and start investing today!
$1.05B
-
0.00%
1.2M
$8.89
$8.43
$8.67
$24.40
$8.36
RLAY FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in RLAY
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.